Glenmark Pharmaceuticals ltd
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Jul has averaged the highest return (+8.7%); Jan the lowest (-4.3%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.9%Neutral MonthJan 2026: -0.93% | +6.0%Positive MonthFeb 2026: +5.99% | -0.2%Neutral MonthMar 2026: -0.21% | +12.8%Positive MonthApr 2026: +12.76% | -6.1%Negative MonthMay 2026: -6.08% | -2.4%Negative MonthJun 2026: -2.40% | +1.5%Neutral MonthJul 2026: +1.52% | +9.0%*Positive MonthAug 2026: +9.00% | β | β | β | β |
| 2025 | -9.7%Negative MonthJan 2025: -9.72% | -12.0%Negative MonthFeb 2025: -11.96% | +20.4%Positive MonthMar 2025: +20.43% | -10.4%Negative MonthApr 2025: -10.36% | +5.6%Positive MonthMay 2025: +5.59% | +20.3%Positive MonthJun 2025: +20.26% | +21.7%Positive MonthJul 2025: +21.68% | -9.8%Negative MonthAug 2025: -9.80% | +1.5%Neutral MonthSep 2025: +1.48% | -3.2%Negative MonthOct 2025: -3.19% | +3.0%Positive MonthNov 2025: +3.01% | +4.6%Positive MonthDec 2025: +4.55% |
| 2024 | +6.5%Positive MonthJan 2024: +6.52% | +1.8%Neutral MonthFeb 2024: +1.78% | +3.4%Positive MonthMar 2024: +3.42% | +10.3%Positive MonthApr 2024: +10.30% | +9.9%Positive MonthMay 2024: +9.90% | +6.0%Positive MonthJun 2024: +6.02% | +19.3%Positive MonthJul 2024: +19.31% | +18.2%Positive MonthAug 2024: +18.16% | -3.5%Negative MonthSep 2024: -3.53% | +1.2%Neutral MonthOct 2024: +1.18% | -9.8%Negative MonthNov 2024: -9.76% | +5.3%Positive MonthDec 2024: +5.29% |
| 2023 | -9.5%Negative MonthJan 2023: -9.48% | +11.6%Positive MonthFeb 2023: +11.59% | +8.4%Positive MonthMar 2023: +8.44% | +21.3%Positive MonthApr 2023: +21.31% | +5.9%Positive MonthMay 2023: +5.89% | +13.1%Positive MonthJun 2023: +13.15% | +18.1%Positive MonthJul 2023: +18.14% | -3.9%Negative MonthAug 2023: -3.93% | +11.4%Positive MonthSep 2023: +11.43% | -12.6%Negative MonthOct 2023: -12.55% | +4.3%Positive MonthNov 2023: +4.32% | +9.5%Positive MonthDec 2023: +9.52% |
| 2022 | -7.8%Negative MonthJan 2022: -7.84% | -7.8%Negative MonthFeb 2022: -7.84% | -1.5%Neutral MonthMar 2022: -1.46% | -0.5%Neutral MonthApr 2022: -0.50% | -10.5%Negative MonthMay 2022: -10.55% | -1.7%Neutral MonthJun 2022: -1.68% | -1.6%Neutral MonthJul 2022: -1.63% | -2.5%Negative MonthAug 2022: -2.47% | +4.7%Positive MonthSep 2022: +4.66% | +4.1%Positive MonthOct 2022: +4.07% | +6.5%Positive MonthNov 2022: +6.52% | -1.5%Neutral MonthDec 2022: -1.45% |
| 2021 | β | β | β | β | β | +10.2%Positive MonthJun 2021: +10.16% | -6.9%Negative MonthJul 2021: -6.92% | -12.7%Negative MonthAug 2021: -12.71% | -3.8%Negative MonthSep 2021: -3.76% | -1.2%Neutral MonthOct 2021: -1.23% | +3.8%Positive MonthNov 2021: +3.79% | +1.0%Neutral MonthDec 2021: +0.97% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 6 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ9.23 K Cr | β | βΉ1.61 K Cr | β | β | 6.6% | 16.9% | -68.8% |
| Mar 2024 | βΉ7.89 K Cr | β | βΉ5.17 K Cr | β | β | 22.5% | -4.0% | 327.4% |
| Mar 2023 | βΉ8.22 K Cr | β | βΉ1.21 K Cr | β | β | 6.8% | 1.0% | -39.5% |
| Mar 2022 | βΉ8.14 K Cr | β | βΉ2.00 K Cr | β | β | 11.9% | 7.6% | 21.2% |
| Mar 2021 | βΉ7.57 K Cr | β | βΉ1.65 K Cr | β | β | 11.1% | 12.7% | 21.7% |
| Mar 2020 | βΉ6.71 K Cr | β | βΉ1.35 K Cr | β | β | 10.2% | 6.5% | -16.5% |
| Mar 2019 | βΉ6.30 K Cr | β | βΉ1.62 K Cr | β | β | 13.6% | 14.2% | 60.0% |
| Mar 2018 | βΉ5.52 K Cr | β | βΉ1.01 K Cr | β | β | 9.8% | -30.9% | -52.6% |
| Mar 2017 | βΉ7.99 K Cr | β | βΉ2.14 K Cr | β | β | 22.7% | 30.6% | 44.3% |
| Mar 2016 | βΉ6.12 K Cr | β | βΉ1.48 K Cr | β | β | 20.1% | 20.2% | 47.2% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 2,301 | 5,086 | 6,115 | 7,989 | 5,520 | 6,305 | 6,713 | 7,568 | 8,142 | 8,221 | 7,891 | 9,226 | 8,194 |
| Total Expenses | 1,805 | 3,618 | 4,349 | 5,089 | 4,417 | 4,977 | 5,407 | 5,676 | 6,453 | 6,748 | 6,649 | 6,982 | 6,810 |
| EBIT / Operating Profit | 496 | 1,467 | 1,766 | 2,900 | 1,103 | 1,328 | 1,305 | 1,892 | 1,689 | 1,473 | 1,242 | 2,244 | 1,385 |
| OPM % | 22% | 29% | 29% | 36% | 20% | 21% | 19% | 25% | 21% | 18% | 16% | 24% | 17% |
| Other Income | 67 | -86 | 116 | -89 | 326 | 954 | 624 | 469 | 1,044 | 490 | 6,238 | 177 | -861 |
| Finance Costs | 31 | 30 | 36 | 153 | 191 | 224 | 256 | 266 | 236 | 207 | 277 | 49 | 60 |
| Depreciation & Amortisation | 30 | 119 | 100 | 105 | 96 | 106 | 139 | 151 | 160 | 184 | 202 | 219 | 227 |
| Profit Before Tax | 502 | 1,232 | 1,747 | 2,553 | 1,143 | 1,952 | 1,535 | 1,944 | 2,337 | 1,572 | 7,001 | 2,154 | 235 |
| Tax % | 14% | 18% | 15% | 16% | 11% | 17% | 12% | 15% | 15% | 23% | 26% | 25% | - |
| Net Profit / PAT | 434 | 1,008 | 1,484 | 2,141 | 1,014 | 1,622 | 1,355 | 1,649 | 1,998 | 1,209 | 5,167 | 1,610 | 153 |
| EPS (βΉ) | 15.99 | 37.14 | 52.60 | 75.86 | 35.95 | 57.49 | 48.01 | 58.46 | 70.80 | 42.84 | 183.12 | 57.07 | 5.41 |
| Dividend Payout % | 12% | 5% | 4% | 3% | 6% | 3% | 5% | 4% | 4% | 6% | 1% | 4% | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals ltdthis co. | βΉ56.65 K Cr | βΉ9.23 K Cr | 38.50 | 2.37 | 7.33 | 16.9% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
